In vitro studies demonstrating the induction of programmed cell death by cytotoxic drugs used in anticancer chemotherapy suggested that antileukemic treatment eliminates leukemia cells by apoptosis. We therefore analyzed apoptosis induction and activation of apoptosis signaling molecules in patients receiving remission induction treatment for AML and ALL during the initial phase of leukemia cell reduction. A coexistence of distinct populations of CD34 þ and CD34 À leukemia cells could be identified. During chemotherapy, CD34
Introduction
Progress in the treatment of acute leukemia has been achieved by the development of empirically designed chemotherapy protocols applying different cytotoxic drugs in an optimized time course. Leukemia cell reduction through antileukemic therapy may be caused by the inhibition of proliferation or direct induction of cell death. In vitro studies with tumor and leukemia cell lines have shown that cytotoxic drugs used in anticancer chemotherapy induce cell death by the activation of diverse apoptosis signaling pathways. 1, 2 The inhibition of caspase activation, 3 mitochondrial apoptosis signaling 4, 5 or CD95 death receptor signaling 6 could protect cells from cytotoxic druginduced apoptosis in vitro. Thus, defective apoptosis signaling conferred drug resistance in these experimental systems. From such in vitro studies, it has been suggested that functional defects in apoptosis signaling molecules or deficient activation of apoptosis pathways are responsible for chemotherapy resistance and treatment failure in acute leukemia. The involvement of apoptosis in anticancer chemotherapy is also supported by studies demonstrating changes of death receptor gene expression levels 7, 8 in primary leukemia cells upon drug treatment in vitro.
Several studies have correlated constitutive apoptosis gene expression of caspases, [9] [10] [11] mitochondria-related molecules [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] and death receptors [25] [26] [27] to treatment outcome in order to identify apoptosis signaling molecules relevant for leukemia therapy. However, for most of the molecules analyzed, either controversial results were reported or no correlation of expression and treatment outcome was found. Thus, a definite role of apoptosis in leukemia chemotherapy in vivo could not be established by these studies.
So far, few studies have analyzed apoptosis in leukemia cells during antileukemic treatment in vivo. The detection of apoptotic leukemia cells in peripheral blood during chemotherapy failed, possibly because of the rapid removal of proapoptotic cells from the circulation. 28 The induction of apoptosis by chemotherapy has therefore been investigated by assessment of apoptosis after in vitro culture before and during cytotoxic drug treatment in vivo. We have recently reported that in peripheral lymphocytes, proapoptotic changes induced by chemotherapy in vivo are readily detectable. 29 In contrast, in myelocytic leukemia attenuated apoptosis rather than an increase of apoptosis was found during chemotherapy. 21 A recent study reported chemotherapy-induced apoptosis in some of the leukemia samples analyzed. 30 However, the interpretation of these data is difficult, since apoptosis was measured in the whole population of peripheral mononuclear cells, including normal lymphocytes. Thus, the role of apoptosis in remission induction chemotherapy has not been defined and scant data are available on changes in the expression levels of apoptosis genes during initial treatment in vivo.
We therefore investigated whether remission induction treatment for acute leukemia initiates apoptosis and activation of apoptosis molecules in peripheral blood leukemia cells. Analysis of leukemia cell apoptosis in peripheral blood is generally confounded by a relative increase of normal peripheral blood cells during treatment. Cell death analysis was therefore combined with a leukemia-specific marker and with additional analysis for the immature CD34 þ subpopulation of leukemia cells. We found that remission induction treatment in vivo depletes the immature subpopulation of CD34 þ AML and ALL leukemia cells and induces proapoptotic changes in this subpopulation. No changes of CD95 sensitivity, Bcl-2 and Bax expression could be detected in CD34 þ and CD34 À leukemia cells during chemotherapy, indicating the induction of apoptosis independent of activation of the CD95 system or alterations in protein levels of Bax and Bcl-2.
Patients and methods

Patients and treatment
In total, 23 patients with previously untreated acute leukemia were included in this study after informed consent by the patient or their parents. The study was performed according to the institutional guidelines after approval by the committee for human studies. In all, 12 adults with AML were treated with idarubicin, high-dose cytarabine and etoposide for remission induction at the Department for Internal Medicine of the University Hospital Ulm. A total of 11 pediatric patients were treated at the University Children's Hospital Ulm. Remission induction therapy for seven children with ALL consisted of 7 days prednisone 60 mg/m 2 according to the ALL BFM 95 protocol. Four children with AML were treated according to the AML BFM 93 protocol with ADE (cytarabine, daunorubicin and etoposide) or AIE (cytarabine, idarubicin and etoposide) as initial first-line treatment.
Samples
Peripheral blood samples were obtained at presentation and during remission induction treatment. Leukemia blasts were isolated by Ficoll-Hypaque density gradient centrifugation (Ficoll, density 1.077 g/l, Biochrome KG, Berlin, Germany) at 300 g for 25 min at 201C, washed twice with Hank's balanced salt solution supplemented with 2% fetal calf serum (HBSS/FCS) at 41C, and adjusted to 10 7 /ml. Samples were processed directly after isolation, without cryopreservation.
Analysis of leukemia cell subpopulations
Cell analysis was performed by flow cytometry on a FACSCalibur s Cytometer (Becton Dickinson, Heidelberg, Germany) equipped with a 488 nm argon and a 650 nm red diode laser. A total of 0.5-1.0 Â 10 6 cells per test were stained for 25 min at 41C with a combination of fluorochrome-conjugated monoclonal antibodies (mAbs) for CD34, CD33 and CD13 in case of AML, and CD34, CD19 and CD10 in case of ALL. The antibodies CD19 FITC or PE, CD10 PE and CD13 FITC were purchased from Coulter/Immunotech (Krefeld, Germany), CD34 PerCP and CD33 PE from Becton Dickinson (Heidelberg, Germany). For each mAb, an isotype-matched immunoglobulin was used as a control in all experiments. Samples were washed with HBSS supplemented with 2% bovine serum albumin (Serva, Heidelberg, Germany) and 0.2% azide (Merck, Darmstadt, Germany). After fixation with 2% paraformaldehyde, samples were immediately analyzed on a FACSCalibur s Cytometer. A minimum of 50 000 events per sample was acquired, stored in list mode files and subsequently analyzed with Cellquest s software (Becton Dickinson). The percentage of CD34 þ leukemia cells was assessed in the CD19 or CD33 vs CD34 dot blot. Absolute CD34 and CD33 or CD19 cell numbers were calculated from the absolute leukocyte count, the percentage of leukemia blasts in the differential and the percentage of CD34 and CD33 or CD19 þ cells in the blast gate. The reduction of absolute leukemia cell count during treatment was calculated according to the formula: 100À[(100 Â absolute cell number before therapy)/(absolute cell number on day 3 or 4)].
Analysis of CD95 expression and sensitivity on leukemia subpopulations: CD95 expression was analyzed by staining peripheral MNC with anti-CD95 APC in combination with AML-or ALL-specific surface markers (AML: CD34, CD33 and CD13; ALL: CD34, CD19 and CD10). For each mAb, an isotype-matched immunoglobulin was used as a control in all experiments. The mean fluorescence intensity ratio (MFI ratio) for each sample was calculated from the MFI of the CD95-specific antibody divided by the MFI of the isotype control for the respective cell population. Cell death assays: Isolated MNCs from patients undergoing chemotherapy were seeded in 24-well plates at 1.0 Â 10 6 /ml in RPMI 1640 (GIBCO-BRL, Paisley, UK) with the standard supplements 10% heat-inactivated FCS (Biochrom KG, Berlin, Germany), L-glutamine 200 mM and penicillin/streptomycin 100 U/ml. For analysis of CD95-and cytarabine-induced death, blasts were incubated at 371C in a humidified atmosphere containing 5% CO 2 with or without apoptosis-inducing anti-CD95 (APO-1 IgG3) 1 mg/ml or cytarabine 10 mg/ml (kindly provided by Pfizer, Karlsruhe, Germany) for 24 h. Apoptosis was analyzed in leukemia subpopulations by flow cytometric measurement of CD34, CD19 or CD33 expression in combination with annexin V binding and forward/side scatter analysis.
Analysis of
Results
Peripheral leukemia cell reduction and in vitro apoptosis during remission induction therapy
The kinetic of leukemia cell depletion from peripheral blood was analyzed in nine patients with AML and nine patients with ALL during remission induction treatment. Treatment consisted of high-dose cytarabine days 0-4 and idarubicin/etoposide on day 2. Patients with ALL were treated with prednisolone 60 mg/m 2 for 7 days. As depicted in Figure 1 , the white blood count rapidly declined within 4 days. Apoptosis was analyzed in peripheral blood mononuclear cells isolated before (day 0) and during treatment (days 1-3) after in vitro culture for 24 h. In the analysis of the overall population, no increase of spontaneous in vitro apoptosis could be detected (data not shown). Since these analyses could have been confounded by increasing proportions of lymphocytes, peripheral blood leukemia cells were identified by the surface marker expression of CD33 or CD19 in the blast gate. As shown in Figure 1b , in vitro apoptosis did not increase in AML patients and in only one of seven ALL samples. Thus, remission induction treatment rapidly depleted leukemia cells from peripheral blood without the induction of detectable proapoptotic changes in the overall population of peripheral leukemia cells.
Identification of immature leukemia cells by analysis of CD34 expression
Similar to normal hematopoiesis, a hierarchy of primitive leukemia stem cells differentiating to mature leukemia cells has been identified. In order to discriminate mature leukemia cells from immature leukemia cell precursors, we investigated þ and CD34 À cells did not differ in forward/side scatter properties (data not shown). The proportion of leukemia cells expressing CD34 ranged from 0 to 85.7% in AML and 1.5 to 74.5% in ALL as shown in Figure 2b . Thus, the expression of CD34 among leukemia cells is heterogeneous and in most patients two subpopulations of leukemia cells can be distinguished by the analysis of CD34 expression.
Reduction of CD34
þ and CD34 À leukemia cells by remission induction treatment
We next investigated whether the leukemia cell subsets identified by CD34 expression were equally reduced during remission induction treatment. In Figure 3a , the rapid reduction of peripheral leukemia cells in patient AML#3 and ALL#5 is 
À leukemia cells revealed a predominant reduction of the immature CD34
þ leukemia cell population in both patients compared to CD34 À leukemia cells (Figure 3c ). In the ALL patient, the absolute number of mature leukemia cells remained almost unchanged. In order to analyze differential reduction of leukemia cells in a larger number of patients, reduction of leukemia cells was calculated from the initial peripheral blast count and the absolute leukemia cell number at day 2 after 48 h of treatment. As shown in Figure 3d , reduction of immature CD34 þ leukemia cells was generally higher than that in CD34 À cells. In three cases of ALL and two cases of AML, the absolute number of mature leukemia cells even increased, resulting in negative values for leukemia cell reduction in the graph. The data show that remission induction treatment eliminates the immature subpopulation of CD34 þ leukemia cells.
Analysis of in vitro apoptosis during in vivo remission induction therapy
The detection of apoptosis in vivo by morphological changes, DNA fragmentation or phosphatidylserine externalization is prevented by the rapid clearance of apoptotic cells from peripheral blood. We therefore analyzed ex vivo apoptosis of peripheral leukemia cells after 24 h cultivation during in vivo chemotherapy. The representative experiment in Figure 4a shows only a minor increase of apoptotic cells in the whole population of peripheral blood mononuclear cells from day 0 to day 2. By gating on the CD34 þ and CD34 À leukemia cells, we found only 0.7% annexin V-positive cells in both subpopulations before chemotherapy. After 48 h of treatment, clear differences in the leukemia cell subpopulations were seen: in the mature CD34 À population, apoptosis increased to 9.4%, while in the immature population of CD34 þ cells, a marked increase to 54% was found. For further 12 patients, the increase of in vitro apoptosis was calculated by comparison of annexin V-positive cells before and after 48 h of therapy (Figure 4b) . Again, in the immature population of CD34-expressing leukemia cells, a marked increase in apoptosis was detected after 48 h of remission induction treatment, while no such increase could be detected in the mature CD34 À cells. In line with the predominant depletion of CD34 þ leukemia cells in vivo, the data show that remission induction treatment primarily targets the immature population of CD34-expressing leukemia cells for the induction of apoptosis.
Induction of apoptosis by in vitro drug treatment
We next investigated whether differential induction of apoptosis in leukemia cell subpopulations is also found during drug treatment in vitro. As shown in Figure 5a , treatment of leukemia 
Chemotherapy-induced apoptosis in CD34
þ leukemia cells K Stahnke et al cell sample AML#5 with cytarabine in vitro induced significant apoptosis predominantly in immature CD34 þ AML cells (55%) compared to the mature CD34 À blasts (14%). Further 12 samples of AML and ALL patients were analyzed for cytarabine-induced apoptosis in vitro. In the six ALL B precursor leukemias, spontaneous in vitro apoptosis was high already in the untreated samples and cytarabine-specific apoptosis could either not be detected or was too low for a reasonable comparison of apoptosis in leukemia cell subpopulations (data not shown). In AML samples (Figure 5b ), apoptosis sensitivity was also high in the CD34 þ population. Cytarabine increased cell death in both mature and immature populations. However, due to the high base line apoptosis in the CD34 þ population, calculated drug-specific apoptosis, subtracting spontaneous in vitro cell death as in Figure 4b , was not significantly different in the two groups. Thus, differential apoptosis sensitivity of the leukemia cell subpopulation was also found in vitro, but the high drug-induced apoptosis in CD34 þ leukemia cells seen in vivo is not directly recapitulated in all cases in vitro.
Activation of the CD95 system and Bcl-2 and Bax expression levels during remission induction in vivo After the identification of the leukemia cell subpopulation relevant for apoptosis induction, we investigated involvement of the CD95 system in apoptosis induction by antileukemic treatment. Constitutive CD95 expression was higher in mature CD34
À cells. No increase of receptor expression could be detected during remission induction treatment with prednisolone in ALL and cytarabine in AML (Figure 6a and b) . However, after anthracycline treatment of AML patients in vivo, CD95 expression constantly increased in both mature and immature AML cells (Figure 6c ). The data show that CD95 receptor expression is induced by anthracyclines, but not by corticosteroid or cytarabine treatment for remission induction, indicating differences in cellular response to different types of cytotoxic drugs.
Induction of sensitivity towards the CD95 signal is a prerequisite for the involvement of the CD95 system in druginduced apoptosis by antileukemic treatment in vivo. As shown in Figure 7 , no constitutive CD95 sensitivity was found in mature or immature ALL leukemia cells (day 0) and CD95 sensitivity was not induced during treatment (days 1-3). Also in AML, CD95 sensitivity was low before treatment and CD95 sensitivity did not increase after treatment with cytarabine (days 1and 2) or anthracyclines (day 3), except for one patient (AML#5). Thus, despite the induction of CD95 receptor expression by anthracyclines, CD95 death receptor signaling is generally not activated during remission induction treatment for AML and ALL.
We also investigated changes in expression levels of Bcl-2 and Bax during remission induction treatment (data not shown). Bcl-2 levels tended to be higher in AML compared to ALL. There was no constant pattern of changes in the expression levels of Bcl-2 or Bax during treatment. In particular, no constant proapoptotic changes in Bcl-2 and Bax expression could be detected, indicating that the induction of apoptosis during remission induction does not involve the regulation of Bcl-2 and Bax protein expression levels.
Discussion
In this study, we investigated the role of apoptosis and activation of apoptosis signaling molecules in remission induction treatment of acute leukemia. We hypothesized that induction of apoptosis in leukemia cells and activation of apoptosis signaling molecules should be detectable during the initial remission induction treatment, which rapidly eliminates leukemia cells from peripheral blood and bone marrow. 
Chemotherapy-induced apoptosis in CD34
þ leukemia cells K Stahnke et al Leukemia cells from bone marrow and peripheral blood appeared homogeneous by morphological and flow cytometric light scatter criteria. Interestingly, we found a coexistence of CD34 þ and CD34 À leukemia cells in most of the patients analyzed. Similar to normal hematopoiesis, in leukemia, the existence of a hierarchy of primitive stem cells differentiating to mature leukemia cells has been suggested. [31] [32] [33] [34] [35] [36] Clonogenic cells are considered to be predominantly present in the fraction of CD34 þ cells, 33, 37 indicating that CD34 characterizes an immature stage of maturation in leukemia cells (Table 1) .
By analysis according to CD34 expression, we identified striking functional differences in these leukemia cell subpopulations in response to remission induction treatment. The immature CD34
þ leukemia cell population was preferentially reduced by remission induction treatment. Moreover, also the induction of apoptosis was largely restricted to the immature leukemia cell subpopulation. This suggests that the CD34 þ leukemia cell population is the primary target for apoptosis induction by remission induction treatment in vivo. The elimination of CD34 þ leukemia cells from peripheral blood therefore reflects the efficacy of apoptosis induction by antileukemic treatment, while reduction of the nonclonogenic mature leukemia cells may depend on their constitutive tendency towards spontaneous apoptosis.
The differential sensitivity of leukemia cell subpopulations and restriction of apoptosis induction to the CD34 þ cells also clarifies former difficulties in the analysis of drug-induced apoptosis in vivo and in vitro. The immature subpopulation is sometimes small and predominantly decreases day by day with the onset of treatment, resulting in a relative increase of mature cells with unchanged apoptosis rates. Analysis of apoptosis in the overall leukemia cell population therefore often fails to detect the induction of apoptosis by chemotherapy and may even result in the measurement of attenuated apoptosis during treatment.
However, the determinants for apoptosis sensitivity of immature leukemia cells are not clear. In a recent study, differences in cell cycle status have been found in leukemia cell subpopulations gated according to CD34 expression. 38 In our own analyses in single patients, we also found a higher proportion of cells in the S and G2 phases in immature leukemia cells compared to the mature subpopulation (data not shown). A proliferative state might render these cells more susceptible towards DNA-damaging agents and apoptosis. In contrast, low apoptosis sensitivity has been reported for the population of true leukemia stem cells in AML, represented by a small subpopulation of CD34 þ leukemia cells identified by the lack of CD38 expression. [39] [40] [41] Failure of apoptosis induction in this true stem Analysis of CD95 sensitivity during remission induction treatment. Peripheral blood mononuclear cells from six AML (upper panel) and five ALL patients (lower panel) were analyzed for CD95 sensitivity before therapy (day 0) and during antileukemic treatment (days 1-3) consisting of prednisolone in ALL and cytarabine and daunorubicine/idarubicine starting on day 2 in AML. Cells were cultured in medium with and without death-inducing anti-CD95 for 24 h. Apoptosis was measured by annexin V binding in three-color flow cytometry on leukemia cells positive (CD33/CD34 or CD19/ CD34) or negative for CD34 (CD33sp or CD19sp). The percentage of CD95-specific cell death was calculated from apoptosis in anti-CD95-treated and -untreated samples as described in the Patients and methods section.
þ leukemia cells K Stahnke et al cell compartment might explain the recurrence of the disease despite successful reduction of CD34 þ leukemia cells by remission induction treatment.
Our analysis of drug-induced apoptosis in vitro shows that the differential apoptosis sensitivity in vivo is also found in an in vitro assay. However, the predominant apoptosis induction in CD34 þ leukemia cells is not reproduced in all cases. Additional proapoptotic stimuli, such as cytokine and adhesion molecule withdrawal, inducing high spontaneous apoptosis confound the result in vitro. In addition, inhibition of proliferation by in vitro culture may abrogate the predominant drug-induced apoptosis in the CD34 þ leukemia cells in vitro. Still, analysis of leukemia cell subpopulations might enhance the predictive value of in vitro drug resistance assays.
The identification of the target leukemia cell population for apoptosis induction by antileukemic treatment enabled us to analyze apoptosis signaling molecules involved in drug-induced apoptosis in cancer cell lines. No significant alterations in Bax and Bcl-2 expression levels were detected during antileukemic treatment. In line with our data, rather an increase than decrease of Bcl-2 levels during treatment has been reported. 42 In addition, the Bax to Bcl-2 ratio was not altered towards a proapoptotic state. This suggests that remission induction treatment does not induce proapoptotic changes by alteration of protein expression levels of these mitochondria-regulating molecules. However, conformational changes of Bax or cellular localization towards mitochondria might occur independent of changes in protein expression. The data indicate substantial differences in apoptosis induction through antileukemic treatment in vivo compared to apoptosis induction in cancer and leukemia cell lines, in which increase of Bax expression at the RNA and protein levels has been found in p53-mediated and druginduced apoptosis. 43, 44 Constitutive expression of the CD95 receptor and sensitivity for CD95-mediated apoptosis was low in CD34 þ cells in AML and ALL. In contrast, Iijama et al 27 and Wuchter et al 19 reported sensitivity for the CD95 signal in a large proportion of AML samples. This may result from differences in cell sources, since these studies used leukemia samples after cryopreservation, which might sensitize for the CD95 signal. In line with our data, Li et al 45 reported constitutive CD95 resistance in directly analyzed samples. During remission induction treatment, CD95 receptor expression was enhanced only after treatment with daunorubicine, which is in line with previous reports on the induction of the CD95 receptor by anthracyclines in vitro. 7 However, antileukemic treatment in vivo with daunorubicin, prednisolone or cytarabine, or did not induce CD95 sensitivity in peripheral leukemia cells. Since the induction of sensitivity towards the CD95 signal is a prerequisite for involvement of the CD95 system in drug-induced apoptosis, our results largely rule out the fact that remission induction treatment induces apoptosis via activation of the CD95 signaling pathway. Thus, cytotoxic drug-mediated activation of the CD95 system identified in cancer cell lines and in particular in lymphoblastic leukemia cell lines 46, 47 does not appear to contribute to apoptosis induction by remission induction treatment in vivo.
Taken together, we found that apoptosis induction by remission induction therapy in vivo is restricted to the immature population of CD34 þ leukemia cells and defined the role of the CD95 system and of Bcl-2/Bax expression in apoptosis induction in this phase of treatment. Analysis of particular subsets of leukemia cells is required for the identification of apoptosis signaling molecules activated by antileukemic treatment and for the assessment of drug efficacy in vivo and in vitro. Chemotherapy-induced apoptosis in CD34 þ leukemia cells K Stahnke et al
